<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956072</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62063</org_study_id>
    <secondary_id>EORTC-62063</secondary_id>
    <secondary_id>EU-20955</secondary_id>
    <secondary_id>EUDRACT-2007-002257-23</secondary_id>
    <secondary_id>NOVARTIS-EORTC-62063</secondary_id>
    <nct_id>NCT00956072</nct_id>
  </id_info>
  <brief_title>Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate</brief_title>
  <official_title>A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients With Metastatic Gastro-intestinal Stromal Tumor Responding to Imatinib Mesylate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Surgery may remove residual disease in patients with gastrointestinal stromal&#xD;
      tumor that is responding to imatinib mesylate. It is not yet known whether surgery is more&#xD;
      effective than continued imatinib mesylate in treating patients with metastatic&#xD;
      gastrointestinal stromal tumor.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying giving imatinib mesylate therapy&#xD;
      together with surgery to see how well it works compared with imatinib mesylate alone in&#xD;
      treating patients with metastatic gastrointestinal stromal tumor that is responding to&#xD;
      imatinib mesylate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate whether surgery of residual disease improves the progression-free survival of&#xD;
           patients with metastatic gastrointestinal stromal tumor responding to imatinib mesylate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate the pharmacokinetics of imatinib mesylate and its metabolites before and after&#xD;
           randomization.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to center, site of&#xD;
      tumor origin (stomach vs small bowel vs others), and site of metastases (liver vs abdominal&#xD;
      cavity vs both). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo surgery of residual disease. Patients will then resume imatinib&#xD;
           mesylate therapy according to standard of care as soon as possible after surgery (as&#xD;
           soon as the patient restarts taking oral feeding).&#xD;
&#xD;
        -  Arm II: Patients receive imatinib mesylate therapy according to standard of care.&#xD;
&#xD;
      Patients complete quality of life questionnaires at baseline; immediately after hospital&#xD;
      discharge (arm I only); and at 5, 11, and 23 months. Blood samples may be collected for&#xD;
      pharmacokinetic studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 5 years and&#xD;
      then every 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual&#xD;
  </why_stopped>
  <start_date>May 2009</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological response to imatinib mesylate according to RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete resection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by EORTC QLQ-C30</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo surgery of residual disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive imatinib mesylate therapy according to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Patients receive imatinib mesylate</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Patients undergo surgery</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed gastrointestinal stromal tumor expressing CD117+ or with&#xD;
             documented mutation of the KIT or PDGFRA gene&#xD;
&#xD;
          -  Metastatic disease (liver and/or abdominal cavity)&#xD;
&#xD;
               -  No extra-abdominal metastases&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  Achieved complete response, partial response, or stable disease without progression&#xD;
             since the start of imatinib mesylate therapy, documented according to RECIST&#xD;
&#xD;
          -  Underwent 6-12 months of treatment with imatinib mesylate as a standard of care or&#xD;
             within other clinical studies (surgery should be feasible before the end of the 12th&#xD;
             month from imatinib mesylate onset)&#xD;
&#xD;
          -  Surgically resectable residual disease as assessed by CT scan and/or MRI within the&#xD;
             past 14 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  ANC &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 120 μmol/L&#xD;
&#xD;
          -  Albumin &gt; 25 g/L&#xD;
&#xD;
          -  Total bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN (&lt; 5 ULN in case of liver metastases)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 2.5 times ULN (&lt; 5 ULN in case of bone or liver metastases)&#xD;
&#xD;
          -  Negative pregnancy test within the past 14 days&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled hypertension (diastolic BP &gt; 95 mm Hg and systolic BP &gt; 170 mm Hg)&#xD;
&#xD;
          -  No myocardial infarction, unstable, or uncontrolled cardiac disease within the past 6&#xD;
             months&#xD;
&#xD;
          -  No history of arterial thrombosis or deep vein thrombosis within the past year&#xD;
&#xD;
          -  No bleeding diathesis, coagulopathy, or major bleeding within the past 6 months&#xD;
&#xD;
          -  No severe and/or uncontrolled concurrent medical disease, including any of the&#xD;
             following conditions:&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Liver disease, including chronic viral hepatitis judged at risk of reactivation&#xD;
&#xD;
               -  Active infection, including HIV infection&#xD;
&#xD;
          -  No prior malignancy (other than in situ cervical cancer, in situ melanoma, or basal&#xD;
             cell or squamous cell cancer of the skin) unless treated with curative intent and&#xD;
             without evidence of disease for at least 3 years&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior adjuvant or neo-adjuvant imatinib mesylate or other tyrosine kinase inhibitor&#xD;
&#xD;
          -  No coumadin-type anticoagulant &gt; 2mg/day within the past 7 days&#xD;
&#xD;
          -  No major surgery within the past 28 days&#xD;
&#xD;
          -  No medication that interacts moderately or strongly with the CYP3A system within the&#xD;
             past 14 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Gronchi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale per lo Studio e la Cura dei Tumori</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Organization for Research and Treatment of Cancer</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>August 8, 2009</study_first_submitted>
  <study_first_submitted_qc>August 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastrointestinal stromal tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

